Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594413 | 0.88 | ADORA2A (0.57) | ABCG2ABCB1APPCHRNA7TUBB4A | |
| SCHEMBL1593122 | 0.86 | ABCG2 (0.57) | ABCG2ABCB1PIK3CBPIK3CGCHRNA7 | |
| SCHEMBL1592596 | 0.82 | ABCG2 (0.56) | ABCG2APPCHRNA7TUBB4ATUBB | |
| SCHEMBL1592591 | 0.81 | ABCG2 (0.63) | ABCG2ABCB1MAPTSMN1; SMN2ADORA2A | |
| SCHEMBL29609042 | 0.79 | NFKB1 (0.64) | PIK3CBPIK3CGAPPMAPTSMN1; SMN2 | |
| SCHEMBL13326017 | 0.79 | NFKB1 (0.64) | PIK3CBPIK3CGAPPMAPTSMN1; SMN2 | |
| SCHEMBL27835239 | 0.79 | ABCG2 (0.51) | ABCG2ABCB1APPMAPTSMN1; SMN2 | |
| SCHEMBL28929978 | 0.79 | CHRNA7 (0.78) | APPCHRNA7TUBB4ATUBBTUBA3C | |
| SCHEMBL1592678 | 0.78 | CLK4 (0.61) | ABCG2ABCB1MAPTSMN1; SMN2NFKB1 | |
| SCHEMBL8978637 | 0.78 | NFKB1 (0.65) | ABCG2APPMAPTNFKB1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2011-04-21 | — | — | US | disclosed |
| WO-2009118567-A2 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092490-A1 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | HRH2, HRH3, HRH4 | ABCG2 41/4885ABCB1 449/4885PIK3CB 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.